A detailed history of Graham Capital Management, L.P. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 67,956 shares of AMLX stock, worth $358,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,956
Previous 321,867 78.89%
Holding current value
$358,128
Previous $611,000 63.99%
% of portfolio
0.0%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.65 - $3.24 $418,953 - $822,671
-253,911 Reduced 78.89%
67,956 $220,000
Q2 2024

Aug 14, 2024

SELL
$1.62 - $2.71 $328,471 - $549,479
-202,760 Reduced 38.65%
321,867 $611,000
Q1 2024

May 15, 2024

BUY
$2.71 - $19.57 $1.42 Million - $10.3 Million
524,627 New
524,627 $1.49 Million
Q3 2023

Nov 22, 2023

BUY
$18.08 - $23.45 $464,457 - $602,407
25,689 Added 84.08%
56,241 $1.03 Million
Q2 2023

Aug 14, 2023

BUY
$20.98 - $31.42 $640,980 - $959,943
30,552 New
30,552 $659,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $308M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.